Using Carbs to Maxmize results with the Insanity Workout – Video

Posted on by


Using Carbs to Maxmize results with the Insanity Workout
Whether your goal is weight loss or sports performance, using carbhydrates efficiently is the key to success. Click on the link to get our nutrition tips PDF. http://www.insanereport.com FOR MORE WORKOUTS INSANITY TIPS--- http INSANITY NUTRITION TIPS/RESOURCES http://www.thefitclubnetwork.com COACHING--- http://www.thefitclubnetwork.com MY TWITTER: --- twitter.com THE INSANE WARD FACEBOOK GROUP: --- goo.gl ********************************************************************** Insanity Workout Insanity Workout Review Insanity Workout Reviews Insanity Workout Program Insanity Workout TipsFrom:thefitclubnetworkViews:0 0ratingsTime:02:12More inSports

Here is the original post:
Using Carbs to Maxmize results with the Insanity Workout - Video

How To: Renegade Row – Video

Posted on by


How To: Renegade Row
Tutorial on how to do the renegade row. I first got this exercise off of Rusty Moores "Abs Blueprint" booklet, so check that out. Facebook Fan Page: http://www.facebook.com Citadel Nutrition Tier 1 http://www.citadelnutrition.com Interviews Ripped Fitness- rippedfitness.org Kinobody- http://www.kinobody.com Fitness Insane- fitnessinsane.com Royalty free music channel http://www.youtube.com For online personal training/coaching, or video suggestions. Email pureaesthetics93@gmail.com SUBSCRIBE AND LIKEFrom:PureAesthetics93Views:2 2ratingsTime:02:29More inHowto Style

More:
How To: Renegade Row - Video

ANL Day 47 Superfoods or Not – Video

Posted on by


ANL Day 47 Superfoods or Not
Forty seven days complete 100% raw vegan two meals per day at the Academy of Natural Living. In this video I share more about my personal experience undergoing this regime. I also talk about #39;superfoods #39;: what I feel constitutes a #39;superfood #39; and whether or not #39;superfoods #39; as they are conventionally understood have a place in nutrition.From:InNaturesClassroomViews:0 0ratingsTime:11:03More inEducation

View post:
ANL Day 47 Superfoods or Not - Video

Nutrition Group Wants Beyonce To Drop Her $50 Million Pepsi Deal [THE BRIEF]

Posted on by

Good morning, AdLand. Here's what you need to know today:

The Center for Science in the Public Interest wants Beyonce to turn her back on her $50 million deal with Pepsibecause the sugary drink is associated with obesity, diabetes, and heart disease. And if she wants to keep her role as brand ambassador, the nutrition watchdog suggested she donates her proceeds to charity.

Video ads are coming to your Facebook news feed.

Here's why tech marketers are mourning the loss of Gossip Girl.

Check out the winners of theYoung Guns 2012.

Bart Ingram joined brand eCommerce and digital marketing company Acquity Group. He will oversee the Creative Disciplines for the Chicago Studio. He previously served as the head of creative and experience design for the Southeast region at Razorfish.

Quri,a retail measurement service, appointed Jeff Griffin as EVP of sales and business development. He was previously at HookLogic.

Previously on Business Insider Advertising:

More From Business Insider

See more here:
Nutrition Group Wants Beyonce To Drop Her $50 Million Pepsi Deal [THE BRIEF]

Nutrition firm Herbalife to hire 500 at NC plant

Posted on by

WINSTON-SALEM, N.C. (AP) -- Nutrition and weight-loss supplement-maker Herbalife said Wednesday it will revamp a defunct Dell Inc. computer manufacturing plant in North Carolina for an East Coast production center that will employ about 500 in three years.

Los Angeles-based Herbalife will invest about $130 million to buy and equip the 750,000-square-foot Dell plant near Winston-Salem that closed two years ago, company officials and Gov. Beverly Perdue's office said. Herbalife also was reported to be considering a site near Atlanta.

Herbalife will get $1 million up-front from North Carolina taxpayers, and up to $5.5 million more in state tax breaks if the company meets its targets and sustains them for 11 years. The company also could collect $3.4 million in local incentives.

The jobs will pay an average wage of $40,193, below the Forsyth County average of $42,588, state officials said.

Herbalife sells weight management, nutritional and personal-care products exclusively through independent distributors. The company's profit grew 9 percent in the third quarter ending Sept. 30 to $117.8 million as sales increased to $1 billion for the period.

Dell was offered more than $300 million in incentives in 2004 to choose the North Carolina site for its computer assembly plant. Most state incentives were never paid, and Dell repaid local governments $26 million in upfront incentives.

Read more:
Nutrition firm Herbalife to hire 500 at NC plant

Liquid Nutrition Retains CHF Investor Relations

Posted on by

TORONTO, ONTARIO--(Marketwire - Dec 20, 2012) - Liquid Nutrition Group Inc. ("Liquid Nutrition" or "Company") (TSX VENTURE:LQD)(TSX VENTURE:LQD.WT) today announced that it has engaged CHF Investor Relations, a highly regarded Canadian investor relations firm headquartered in Toronto, as its IR partner.

"We are eager to share Liquid Nutrition''s story with a broader investor audience. CHF was selected to provide a solid broker outreach program and ongoing investor relations support that will showcase the Company''s growth and investment opportunity," commented Glenn Young, President and CEO, Liquid Nutrition Group Inc.

Effective immediately, the services agreement for investor relations and market-making is for a term of twelve months to December 31st 2013, and may be extended for up to one year. Under the terms of the services agreement, which is subject to TSX Venture Exchange approval, CHF will receive up to $7,500 per month in fees and reimbursement of expenses. CHF has been granted a total of 78,000 LQD stock options at an exercise price of $0.90 per share. The options vest quarterly over twelve months and have a five-year term. Upon termination of the services agreement, any vested options will be cancelled after 30 days, as is required for TSX Venture''s Tier 2 Issuers.

The market-making activity will be conducted using a registered broker in compliance with Policy 3.4 of the TSX Venture Exchange Corporate Finance Manual (the "Manual"), IIROC''s Universal Market Integrity Rules & Policies (2010) and other relevant policies, so that trading orders in Liquid Nutrition''s shares are made to manage share price volatility and imbalances of orders in order to improve trading liquidity on the exchange. In accordance with Policy 3.4, section 2.8 of the Manual that states in part "an Issuer may not use its own funds, or provide direct or indirect compensation to other parties to undertake a market-making function in its securities," the Company and CHF confirm that capital for the purposes of market-making has not and will not be provided from the Company''s treasury.

Prior to the grant of options outlined above, CHF had no direct or indirect interest in the Company or its securities.

About CHF Investor Relations

CHF''s effective role is acting as the public company''s outsourced, low-cost equivalent to an internal investor relations department. CHF serves an international portfolio of TSX/TSX Venture and CNSX listed companies that operate in a broad range of industries including niche products and business solutions, mining exploration and producers, oil & gas, industrial products and services, biotech and high-tech. The depth of capital market experience at CHF is formidable dating back to the late 1970''s.

About Liquid Nutrition Group Inc.

Liquid Nutrition Group Inc. (LNGI)(TSX VENTURE:LQD)(TSX VENTURE:LQD.WT) is a rapidly growing functional beverage, vitamin and supplement store brand committed to bringing healthy and delicious eating to communities around the world. Through its wholly-owned subsidiary, Liquid Nutrition Franchising Corporation, LNGI has signed franchise agreements for over 80 stores across Canada, as well as license agreement in the Caribbean and the Middle East. For store locations, business opportunities or more information visit http://www.liquidnutrition.com. Please join Liquid Nutrition on Facebook and follow us on Twitter @liquidnutrition.

About Team Liquid

Read the rest here:
Liquid Nutrition Retains CHF Investor Relations

Dr. Myron Cohen 2012 December Commencement Address | UNC-Chapel Hill – Video

Posted on by


Dr. Myron Cohen 2012 December Commencement Address | UNC-Chapel Hill
Myron Cohen, MD, the J. Herbert Bate Distinguished Professor of Medicine, Microbiology and Immunology and Epidemiology at UNC-Chapel Hill delivers the commencement address to graduates. Cohen #39;s work on stopping the spread of HIV was named 2011 #39;s Scientific Breakthrough of the Year by the journal #39;Science. #39;From:UNCChapelHillViews:1 0ratingsTime:15:08More inEducation

Originally posted here:
Dr. Myron Cohen 2012 December Commencement Address | UNC-Chapel Hill - Video

Be Your Own Superhero: Nathan Wecker, microbiology student – Video

Posted on by


Be Your Own Superhero: Nathan Wecker, microbiology student
Nathan already had a great job and a family when he decided he #39;d rather do something he truly enjoyed. Now he #39;s a microbiology major with plans to go on to dental school. See more adventures of real Weber State students on facebook: http://www.facebook.comFrom:wsumarketingViews:1 0ratingsTime:01:51More inEducation

Follow this link:
Be Your Own Superhero: Nathan Wecker, microbiology student - Video

Happy New Year Party 2013 @ SCMU, Microbiology performance.wmv – Video

Posted on by


Happy New Year Party 2013 @ SCMU, Microbiology performance.wmv
"Rak Thai ( #3619; #3634; #3585; #3652; #3607; #3618;)" is the FIRST prize show in NY party 2013 at Faculty of Science, Mahidol University from Department of Microbiology..."All about SCMI...WE are THE ONE".From:Apamas SukkaewViews:1 1ratingsTime:14:52More inPeople Blogs

Go here to see the original:
Happy New Year Party 2013 @ SCMU, Microbiology performance.wmv - Video

Institute of Microbiology – ETH Zurich – Video

Posted on by


Institute of Microbiology - ETH Zurich
SUPPORTED by Hauke Hennecke - Emeritus Professor of Microbiology DIRECTED by Jörg Hennecke - http://www.yorkproduction.ch MUSIC WRITTEN PROGRAMMED by Jörg Hennecke (inspired by Henry Jackman) CAMERA / ANIMATIONS / VIDEO SOUND EDITING by Jörg Hennecke "Peter Pan" - written by Bohdan Mikolasek, performed by Valium21, rearranged edited by Jörg Hennecke http://www.valium.ch "Take My Time" - written by Jochen Hennecke, performed by Days We Are Even (DWAE) http://www.daysweareeven.com Animated protein structures were provided by Kaspar Locher Mareike Kurz © 2012, Institute of Microbiology YorkproductionFrom:yorkproductionViews:152 4ratingsTime:06:18More inEntertainment

Read the rest here:
Institute of Microbiology - ETH Zurich - Video

United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology …

Posted on by

NEW YORK, Dec. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0763017/United-States-In-Vitro-Diagnostics-Market-Outlook-to-2018--Clinical-Chemistry-Genetic-Testing-Haematology-Histology-and-Cytology-Immuno-Chemistry-Infectious-Immunology-and-Microbiology-Culture.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. - 2011 company shares and distribution shares data for each of the seven market categories.- Global corporate-level profiles of key companies operating within the United States In Vitro Diagnosticsmarket. - Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., Alere Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the United States In Vitro Diagnostics competitive landscape.- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.- What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.1 Table of Contents1 Table of Contents 21.1 List of Tables 71.2 List of Figures 132 Introduction 162.1 What is This Report About? 163 In Vitro Diagnostics In United States 173.1 In Vitro Diagnostics, Market Segmentation 173.2 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 183.3 In Vitro Diagnostics Market, United States, Revenue Mix ($m), 2011 203.4 In Vitro Diagnostics Market, United States, Category Contribution (%), 2011 213.5 In Vitro Diagnostics, United States, Company Share (2010-2011) 284 Clinical Chemistry In United States 304.1 Clinical Chemistry, Market Segmentation 304.2 Clinical Chemistry Market, United States, Revenue Mix ($m), 2011 314.3 Clinical Chemistry Market, United States, Segment Contribution (%), 2011 324.4 Clinical Chemistry Overall Revenue, (2004-2018) 334.5 Clinical Chemistry Distribution Share (2010-2011) 454.6 Clinical Chemistry, United States, Company Share (2010-2011) 465 Genetic Testing In United States 475.1 Genetic Testing, Market Segmentation 475.2 Genetic Testing Market, United States, Revenue Mix ($m), 2011 485.3 Genetic Testing Market, United States, Segment Contribution (%), 2011 495.4 Genetic Testing Overall Revenue, (2004-2018) 505.5 Genetic Testing Distribution Share (2010-2011) 545.6 Genetic Testing, United States, Company Share (2010-2011) 556 Haematology In United States 576.1 Haematology Market, Market Segmentation 576.2 Haematology Market, United States, Revenue Mix ($m), 2011 586.3 Haematology Market, United States, Segment Contribution (%), 2011 596.4 Haematology Overall Revenue, (2004-2018) 606.5 Haematology Distribution Share (2010-2011) 846.6 Haematology, United States, Company Share (2010-2011) 857 Histology And Cytology In United States 877.1 Histology and Cytology Market, Market Segmentation 877.2 Histology And Cytology Market, United States, Revenue Mix ($m), 2011 887.3 Histology And Cytology Market, United States, Segment Contribution (%), 2011 897.4 Histology And Cytology Overall Revenue, (2004-2018) 907.5 Histology And Cytology Distribution Share (2010-2011) 947.6 Histology And Cytology, United States, Company Share (2010-2011) 958 Immuno Chemistry In United States 978.1 Infectious Immunology, Market Segmentation 978.2 Immuno Chemistry Market, United States, Revenue Mix ($m), 2011 988.3 Immuno Chemistry Market, United States, Segment Contribution (%), 2011 998.4 Immuno Chemistry Overall Revenue, (2004-2018) 1008.5 Immuno Chemistry Distribution Share (2010-2011) 1288.6 Immuno Chemistry, United States, Company Share (2010-2011) 1299 Infectious Immunology In United States 1319.1 Infectious Immunology Market, United States, Revenue Mix ($m), 2011 1319.2 Infectious Immunology Market, United States, Segment Contribution (%), 2011 1329.3 Infectious Immunology Overall Revenue, (2004-2018) 1339.4 Infectious Immunology Distribution Share (2010-2011) 1419.5 Infectious Immunology, United States, Company Share (2010-2011) 14210 Microbiology Culture In United States 14410.1 Microbiology Culture, Market Segmentation 14410.2 Microbiology Culture Market, United States, Revenue Mix ($m), 2011 14510.3 Microbiology Culture Market, United States, Segment Contribution (%), 2011 14610.4 Microbiology Culture Overall Revenue, (2004-2018) 14710.5 Microbiology Culture Distribution Share (2010-2011) 15510.6 Microbiology Culture, United States, Company Share (2010-2011) 15611 Overview of Key Companies in United States In Vitro Diagnostics Market 15811.1 Siemens Healthcare 15811.2 Abbott Laboratories 15911.3 F. Hoffmann-La Roche Ltd. 16011.4 Beckman Coulter, Inc. 16111.5 Ortho-Clinical Diagnostics Inc. 16211.6 Alere Inc. 16311.7 Danaher Corporation 16411.8 bioMerieux S.A. 16411.9 Becton, Dickinson and Company 16511.10 Bio-Rad Laboratories, Inc. 16511.11 Sysmex Corporation 16611.12 Qiagen N.V. 16611.13 Gen-Probe Incorporated 16711.14 DiaSorin S.p.A 16711.15 Immucor, Inc. 16811.16 Cepheid 16811.17 Thermo Fisher Scientific Inc. 16911.18 Hologic, Inc. 16911.19 PerkinElmer, Inc. 17011.20 Grifols, S.A. 17011.21 Olympus Corporation 17111.22 Horiba, Ltd. 17111.23 Life Technologies Corporation 17211.24 Diagnostica Stago, Inc. 17211.25 ELITech Group 17311.26 OraSure Technologies, Inc. 17312 In Vitro Diagnostics Market Pipeline Products 17412.1 Clinical Chemisty Market Pipeline Products 17412.2 Immuno Chemistry Market Pipeline Products 18112.3 Haematology Market Pipeline Products 19212.4 Infectious Immunology Market Pipeline Products 19412.5 Microbiology Culture Market Pipeline Products 20112.6 Histology And Cytology Market Pipeline Products 20212.7 Genetic Testing Market Pipeline Products 20313 Financial Deals Landscape 20813.1 Acquisition 20813.2 Partnerships 23914 Recent Developments 33014.1 Strategy And Business Planning 33014.2 Research And Development 35314.3 Legal and Regulatory 35914.4 Government and Public Interest 38114.5 Product News 42815 Appendix 52515.1 Definitions of Markets Covered in the Report 52615.2 Research Methodology 53715.3 Secondary Research 53715.4 Primary Research 53815.5 Models 53815.6 Forecasts 53915.7 Expert Panels 53915.8 GlobalData Consulting 53915.9 Contact Us 54015.10 Disclaimer 540

List of Tables

Table 1: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 36Table 2: In Vitro Diagnostics Market, United States, Category Contribution (%), 2011 38Table 3: In Vitro Diagnostics Market, United States, Cross-Category Analysis, 2004-2018 40Table 4: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 42Table 5: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 44Table 6: In Vitro Diagnostics, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 46Table 7: Clinical Chemistry Market, United States, Segment Contribution (%), 2011 49Table 8: Clinical Chemistry, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 51Table 9: Clinical Chemistry, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 53Table 10: Clinical Chemisty Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 55Table 11: Clinical Chemisty Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 57Table 12: Urine Analysis, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 59Table 13: Urine Analysis, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 61Table 14: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 62Table 15: Clinical Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 63Table 16: Genetic Testing Market, United States, Segment Contribution (%), 2011 66Table 17: Genetic Testing, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 68Table 18: Genetic Testing, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 70Table 19: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 71Table 20: Genetic Testing, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 73Table 21: Haematology Market, United States, Segment Contribution (%), 2011 76Table 22: Haematology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 78Table 23: Haematology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 80Table 24: Haematology Reagents, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 82Table 25: Haematology Reagents, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 84Table 26: Immunohaematology, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 86Table 27: Immunohaematology, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 88Table 28: Haemostasis, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 90Table 29: Haemostasis, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 92Table 30: Haematology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 94Table 31: Haematology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 96Table 32: Haematology Cell Counters, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 98Table 33: Haematology Cell Counters, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 100Table 34: Haematology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 101Table 35: Haematology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 103Table 36: Histology And Cytology Market, United States, Segment Contribution (%), 2011 106Table 37: Histology And Cytology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 108Table 38: Histology And Cytology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 110Table 39: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 111Table 40: Histology And Cytology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 113Table 41: Immuno Chemistry Market, United States, Segment Contribution (%), 2011 116Table 42: Immuno Chemistry, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 118Table 43: Immuno Chemistry, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 120Table 44: Disease Specific Immunochemistry, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 122Table 45: Disease Specific Immunochemistry, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 124Table 46: Drugs of Abuse / Toxicology, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 126Table 47: Drugs of Abuse / Toxicology, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 128Table 48: Endocrinology Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 130Table 49: Endocrinology Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 132Table 50: Immunochemistry Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 134Table 51: Immunochemistry Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 136Table 52: Therapeutic Drug Monitoring, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 138Table 53: Therapeutic Drug Monitoring, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 140Table 54: Immunochemistry Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 142Table 55: Immunochemistry Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 144Table 56: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 145Table 57: Immuno Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 147Table 58: Infectious Immunology Market, United States, Segment Contribution (%), 2011 149Table 59: Infectious Immunology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 151Table 60: Infectious Immunology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 153Table 61: Infectious Immunology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 155Table 62: Infectious Immunology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 157Table 63: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 158Table 64: Infectious Immunology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 160Table 65: Microbiology Culture Market, United States, Segment Contribution (%), 2011 163Table 66: Microbiology Culture, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 165Table 67: Microbiology Culture, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 167Table 68: Microbiology Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 169Table 69: Microbiology Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 171Table 70: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 172Table 71: Microbiology Culture, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 174Table 72: Clinical Chemisty Market Pipeline Products 191Table 73: Immuno Chemistry Market Pipeline Products 198Table 74: Haematology Market Pipeline Products 209Table 75: Infectious Immunology Market Pipeline Products 211Table 76: Microbiology Culture Market Pipeline Products 218Table 77: Histology And Cytology Market Pipeline Products 219Table 78: Genetic Testing Market Pipeline Products 220Table 79: ERBA Diagnostics Acquires Drew Scientific, Maker Of Analytical Instruments And Reagents, For $6.5 Million 225Table 80: Measurement Specialties Acquires Cambridge Technologies And Resistance Temperature Detector Company For $18.8 Million 227Table 81: Atossa Genetics Acquires Acueity Healthcare, Diagnostic Device Provider 228Table 82: AccelPath Acquires DigiPath Solutions For $2.4 Million 229Table 83: Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For $324 Million 230Table 84: Charles River Labs Acquires Accugenix, Provider Of Microbe Identification Services, For $17 Million 232Table 85: Leica Biosystems Completes Acquisition Of Aperio Technologies 233Table 86: Metabolon Acquires Lipomics Technologies, Diagnostics Company 235Table 87: Waters Acquires Blue Reference, Maker Of Application Scientific Databases, For $14 Million 237Table 88: Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 238Table 89: Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For $925 Million 239Table 90: Life Technologies Acquires Navigenics 241Table 91: Genova Diagnostics Acquires Metametrix, Clinical Laboratory 243Table 92: Luminex To Acquire GenturaDx, Molecular Diagnostics Company, For $50 Million 244Table 93: Systagenix Acquires O2 Insights 246Table 94: LabCorp Completes Acquisition Of Medtox Scientific For $241 Million 247Table 95: Flagship Biosciences Acquires Ihctech, Provider Of Research Immunohistochemistry And Histology Services 249Table 96: Halo Healthcare Acquires NeoMatrix, Maker Of Diagnostic Equipments 250Table 97: Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 251Table 98: Hologic Completes Acquisition Of Gen-Probe For $3.7 Billion 252Table 99: Haemonetics To Acquire Hemerus Medical, Provider Of Leukoreduction Technologies, For $27 Million 254Table 100: IntegenX Acquires SV, Provider Of DNA Identification Consumable Products, From GE Healthcare Bio-Sciences 255Table 101: DioGenix Enters Into Agreement With Fast Forward To Develop New Blood Test For Multiple Sclerosis 256Table 102: GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 257Table 103: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 259Table 104: CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 260Table 105: Clinical Genomics Enters Into Licensing Agreement With Quest Diagnostics For Colon Cancer Markers 261Table 106: Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 262Table 107: Malvern Instruments Enters Into Co-Marketing Agreement With Affinity Biosensors For Archimedes Particle Metrology System 263Table 108: Exosome Diagnostics Enters Into Co-Development Agreement With Promega For Urine Clinical Sample Concentrator Kit 264Table 109: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 265Table 110: Ezose Enters Into Co-Development Agreement With Fast Forward For Multiple Sclerosis Biomarkers 266Table 111: BioDot Enters Into Co-Marketing Agreement With JOT Automation 267Table 112: Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 268Table 113: LifeTech Scientific, DiNova Venture Partners, Themes Investment Partners And Broncus Technologies Partner To Form Broncus Medical 269Table 114: Van Andel Institute Enters Into Co-Development Agreement With Emory University 270Table 115: Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early Embryo Viability Assessment Test 271Table 116: PGXL Labs Enters Into Joint Venture Agreement With Essential Molecular Testing 272Table 117: Broad Institute Enters Into Distribution Agreement With Appistry For Genome Analysis Toolkit 273Table 118: Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 274Table 119: Sage Labs Enters Into Agreement With Ekam Imaging To Develop Imaging Assays 275Table 120: Bruker Enters Into An Agreement With Nextval For High-throughput Screening Technology 276Table 121: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 277Table 122: RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 278Table 123: Amarantus BioSciences Enters Into Option For Licensing Agreement With Memory Dx For LymPro Blood Test 279Table 124: Iverson Genetic Diagnostics Enters Into Licensing Agreement With Johns Hopkins University School For Molecular Diagnostic Tests 280Table 125: Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 281Table 126: Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 282Table 127: Trillium Diagnostics Enters Into Licensing Agreement With Leukocare For Sepsis Dx 283Table 128: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 284Table 129: Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 285Table 130: Augurex Life Sciences Enters Into Licensing Agreement With Quest Diagnostics For 14-3-3n Biomarker 286Table 131: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions 287Table 132: Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 288Table 133: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 290Table 134: Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 292Table 135: NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 294Table 136: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 295Table 137: Atossa Enters Into Co-Marketing Agreement With Diagnostics Test Group For MASCT System 296Table 138: Genalyte Partners Scienion To Provide Sciflexarrayer Dispensers For Maverick Detection Platform 297Table 139: CML HealthCare Enters Into Agreement With MaRS Innovation 298Table 140: Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 299Table 141: Agilent Technologies Enters Into Co-Marketing Agreement With Molecular Discovery 300Table 142: Agilent Technologies Enters Into Co-Marketing Agreement With MRM Proteomics 301Table 143: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test 302Table 144: Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 303Table 145: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 304Table 146: ImaginAb Enters Into Co-Development Agreement With MacroGenics 305Table 147: BellBrook Labs Enters Into Co-Development Agreement With Reaction Biology 306Table 148: GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 307Table 149: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 308Table 150: Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 309Table 151: Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 310Table 152: Axela Enters Into Co-Marketing Agreement With OvaGene Oncology 311Table 153: University of Michigan Enters Into Joint Venture Agreement With International Genomics Consortium 312Table 154: Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 313Table 155: Curetis Enters Into Licensing Agreement With Cempra For Unyvero 314Table 156: Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 315Table 157: Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers Squibb 316Table 158: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 317Table 159: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics 318Table 160: Affymetrix Expands Licensing Agreement With Siemens Healthcare For Branched DNA Technology 319Table 161: Molecular Targeting Technologies Enters Into Licensing Agreement With Medical College of Wisconsin For 99mTc-HYNIC-Duramycin 320Table 162: Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 321Table 163: Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 322Table 164: Gen-Probe Enters Into Co-Marketing Agreement With Life Technologies 323Table 165: OriGene Technologies Enters Into Co-Development Agreement With Centre of Excellence for Prevention of Organ Failure 324Table 166: Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex 325Table 167: IRIS International Enters Into Distribution Agreement With Alifax 326Table 168: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center 327Table 169: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 328Table 170: Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 329Table 171: RS Medical Enters Into Distribution Agreement With Harvest Technologies 330Table 172: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 331Table 173: Sandia National Labs Plans To Enter Into Licensing Agreement For SpinDx, Medical Diagnostic Tool 332Table 174: HTG Molecular Diagnostics Enters Into Licensing Agreement With Merck For Breast Cancer Marker Patent Portfolio 333Table 175: Genisphere Enters Into Co-Development Agreement With Lankenau Institute for Medical Research 334Table 176: WaferGen Biosystems Enters Into Agreement With Integrated DNA Technologies 335Table 177: BioView Enters Into Co-Development Agreement With ScreenCell For Circulating Tumor Cell Analysis Technology 336Table 178: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 337Table 179: Fluxion Biosciences Enters Into Co-Development Agreement With Stanford University School of Medicine 338Table 180: Merrimack Pharma Enters Into Co-Development Agreement With Cancer Treatment Centers of America 339Table 181: Phenomenome Discoveries Enters Into Licensing Agreement With Polymedco For Cancer Diagnostic Test 340Table 182: PlexPress Enters Into Technology Integration Agreement With Phalanx Biotech 341Table 183: PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 342Table 184: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers For DNA-FISH Assays 343Table 185: Stratos Enters Into Co- Development Agreement With nanoMR 344Table 186: Guided Therapeutics Extends Licensing And Co-Development Agreement With Konica Minolta 345Table 187: Berg Pharma Enters Into Co-Development Agreement With Parkinson's Institute 346

Read more:
United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology ...

The Link – Ong Shunmugam Designs – Video

Posted on by


The Link - Ong Shunmugam Designs
Ong Shunmugam is a contemporary womenswear label with a simple quest to craft beautiful clothes by focusing on sartorial construction instead of fast fashion; on cut and fit before look; on longevity over excess. Designed and made across Asia, their atelier often reworks familiar influences, weaving traditional textile techniques, colours and silhouettes into the modern wardrobe, while deliberately disregarding stereotypes and caricatures. Available only through our atelier, website and a tightly curated guerilla gallery, Ong Shunmugam pieces are often one-offs or produced in lean quantities.From:litvchannelViews:0 0ratingsTime:02:01More inEntertainment

Read more here:
The Link - Ong Shunmugam Designs - Video

Rip Curl Men's E Bomb 3/2MM Chest Zip Fullsuit | SwimOutlet.com – Video

Posted on by


Rip Curl Men #39;s E Bomb 3/2MM Chest Zip Fullsuit | SwimOutlet.com
Get yours at SwimOutlet.com: http://www.swimoutlet.com If you want the best wetsuit with innovative technology, youâ euro; trade;ve found it right here. The E Bomb Fullsuit gives you 4-Way Stretch for an always supreme fit and numerous benefits like Neoprene and E3+, letting you catch the perfect ride every time. E Bomb features state of the art technology to let you surf your best performance every time. Features: 100% E3 Neoprene for the lightest, warmest and most flexible Neoprene ever. 4-Way Back Stretch: Stretches across the back for both paddling and body torque during turns. Breaks the straight seam line across the back, allowing the E3 to do its job without the seam restriction. E3+ Handtape: E3+ is superior to Liquid Taped seams, giving you longevity and integrity of seam seal with 120% more stretch. Glued and Blindstitched: Triple glued, double stitched seam only penetrates one side of the Neoprene. Allows for higher stretch, strength and minimal water entry. Batwing system provides a barrier from water entry and cold water flushes. Seamless underarms and shoulders provide unrestricted flexibility and maximum movement. Chest zip gives you a front closure system that provides the freedom of a zip-free suit with the easy access of a back zip. Drainage system is a 3-hole system that allows excess water to drain freely. Stash pocket gives you an external zip pocket with key loop. Hydro-Loc collar is adjustable to seal the neck and prevent water flushes. S-Flex knees are highly ...From:SwimOutletGearViews:0 0ratingsTime:00:26More inSports

Read the rest here:
Rip Curl Men's E Bomb 3/2MM Chest Zip Fullsuit | SwimOutlet.com - Video

The Link – Ong Shunmugam Profile – Video

Posted on by


The Link - Ong Shunmugam Profile
Ong Shunmugam is a contemporary womenswear label with a simple quest to craft beautiful clothes by focusing on sartorial construction instead of fast fashion; on cut and fit before look; on longevity over excess. Designed and made across Asia, their atelier often reworks familiar influences, weaving traditional textile techniques, colours and silhouettes into the modern wardrobe, while deliberately disregarding stereotypes and caricatures. Available only through our atelier, website and a tightly curated guerilla gallery, Ong Shunmugam pieces are often one-offs or produced in lean quantities.From:litvchannelViews:1 0ratingsTime:02:01More inEntertainment

Here is the original post:
The Link - Ong Shunmugam Profile - Video

Be*Healthy iPhone App Review — Best10Apps.com – Video

Posted on by


Be*Healthy iPhone App Review -- Best10Apps.com
Visit http://www.best10apps.com for more great iPhone and iPad game reviews. Highlight Do you wants to live longer and healthier? I think nobody can say "no". But do you know what can you do to add extra years of healthy living to your life? Well, you can find the answer in Be*Healthy. Be*Healthy is a valuable app that provides a Six-Step Program for improving your health and longevity. Size: 118 MB Learn more: http://www.best10apps.comFrom:iOS BestAppsViews:0 0ratingsTime:06:38More inHowto Style

Read the original post:
Be*Healthy iPhone App Review -- Best10Apps.com - Video